April 4, 2019 7:29am

News: Homology Medicines (FIXX), a genetic medicines company, announced today that the U.S. FDA has provided clearance for Homology to begin its P1/2 pheNIX clinical trial with HMI-102, a one-time gene therapy candidate for adults with the rare genetic disease phenylketonuria (PKU), an inborn error of metabolism.

Financing: Pluristem (PSTI) offering pricing still has not been revealed – transparency question?

Last night I stated, “Build cash positions and “powder” for the coming counter-cycle; it’s not a dig at the sector but, by being tactical - don’t disturb liquidity to enhance portfolio protection”

Pre-open indications: 3 BUY, 4 SELLs and 3 TRADES


You’d be reading if you were a subscriber!

Members only. Please login.